Buprenorphine

Approximately 2 million Americans are affected by opioid dependence and abuse, including the use of heroin and, increasingly, the use of prescription pain medication. There are not enough substance abuse treatment facilities to keep up with this demand, so primary care is becoming a common setting for treatment.

Opioid dependence therapy with buprenorphine is one of the best evidence-based interventions to curb the crisis in the United States. Weitzman ECHO MAT sessions provide the front-line primary care provider and team with the support and expert advice that they need to gain confidence in their management of opioid dependence with buprenorphine.

 

Participant Testimonials

"As new suboxone provider, Project ECHO Buprenorphine has been useful in helping me to manage complex cases, gain more insight into the theory and practice of addiction medicine, feel more comfortable working in the often ambiguous/grey areas of suboxone management, and finding the right patient-provider boundaries and expectations in the harm reduction model.   It is also good for getting practical but hard to track down information (lab interpretation, medication dosing, etc.)."

                               - Andrew Yim, APRN; Community Health Center, Inc., Meriden, CT
 

"I really enjoyed the Project ECHO Buprenorphine session. This is not just how to dose a medication, but teaching an approach to caring for patients with this disease. I am sold."

                              - Josiah Rich, MD, Director of the Center for Prisoner Health and Human Rights; The Miriam Hospital, Providence, RI